Coronary Computed Tomography Angiography After Stress Testing  by Sharma, Abhishek
R239JACC Vol. 60, No. 3, 2012 Correspondence
July 17, 2012:235–41Transcatheter Aortic Valve
Replacement: What’s in a Name?
In the 2012 expert consensus document on transcatheter aortic valve
replacement (TAVR), the inexact name TAVR appears in nearly every
paragraph (1). But, what’s in a name? According to William Shake-
speare, “That which we call a rose; by any other name would still
smell as sweet” (Romeo and Juliette, c. 1597). We therefore humbly
suggest reversion to the archaic name transcatheter aortic valve
implantation (TAVI). TAVR has been characterized as a disrup-
tive technology destined to change the landscape of valvular heart
disease therapy (2). A disruptive technology refers to an innovation
that ultimately displaces a proven technology already on the
market, in this case, surgical valve replacement. But how can we
accept such a bold declaration when the designation of the
procedure is a confusing misnomer?
We increasingly see poor operative candidates with severe aortic
stenosis in our multidisciplinary valve clinic. Our conversation
commences by reviewing the glossy educational pamphlet for the
Edwards Sapien Transcatheter Valve (Edwards Lifesciences LLC,
Irvine, California). The title on the front cover, above the image of
the loving elderly couple sitting on a park bench, reads “Trans-
catheter Aortic Valve Replacement.” Invariably, the first question
from an astute octogenarian is, “What happens to the old valve?”
We gracefully explain that we blow up a balloon, smash the old valve
to the side, then implant a new one within their existing annulus.
Their reaction is often one of bewilderment. This confusion is well
founded. Webster’s dictionary defines replace as “to put something
new in place of something else,” and implies filling a place once
occupied by something removed. One does not have a muffler
replaced at the local auto shop and expect to find the old one still in
place. Technically, we are performing valve displacement. However, a
valve displacement doesn’t sound like an advanced restorative therapy
that marketing experts would embrace.
With commercial release of the Sapien valve on November 2,
2011, the TAVR misnomer was memorialized: “The U.S. FDA
today approved the first artificial heart valve that can replace an
aortic heart valve damaged by senile aortic valve stenosis without
open-heart surgery” (3). Suddenly, the blogosphere described “The
Evolving TAVR Market” at NASDAQ.com, while the cardiology
community further cemented the acronym in catheterization lab-
oratories everywhere.
When did this conspicuous misuse of the English language first
occur? Results of the randomized PARTNER (Placement of
Aortic Transcatheter Valve) trial were published in a 2010 article
entitled “Transcatheter Aortic-Valve Implantation for Aortic Ste-
nosis in Patients Who Cannot Undergo Surgery” (4). TAVI was
the acronym used, and implantation seemed an appropriate de-
scription of the technology. By 2011, with publication of the
high-risk cohort of the PARTNER trial, the title somehow
transformed to “Transcatheter Versus Surgical Aortic-Valve Re-
placement in High-Risk Patients” (5).
Why does this matter? We contend that this is not merely
semantic, because an accurate name for high-risk expensive pro-
cedures is pertinent to healthcare stake holders. It facilitates
uniform communication among researchers, payers, regulators,
clinicians, and, most importantly, patients. In a clinical landscapecluttered with jargon, we should strive toward verbal precision.
Politicians, poets, and pollsters know that words matter. Powerful
words launch social movements and even cultural revolutions. The
right catch phrase also can launch a new product. However, there
should be truth in advertising, and our regulatory bodies should be
critical in determining if advertising is misleading or fails to
disclose all the relevant facts (6).
So what’s in a name? If TAVR is to alter the course of cardiovas-
cular disease care, then we believe this rose would smell sweeter with
a more accurate name. We suggest the original designation of TAVI
be the acronym of choice. This title harkens back to Rudyard Kipling’s
classic novel where the valiant mongoose, Rikki-Tikki-Tavi, con-
fronts a dreaded cobra plotting the murder of his adoptive human
family. Senile critical aortic stenosis in poor operative candidates just
may be the cardiologist’s most poisonous snake. To combat such a foe,
it is fitting that TAVI be anointed our protagonist.
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Coronary Computed Tomography
Angiography After Stress Testing
In the ACIC (Advanced Cardiovascular Imaging Consortium)
registry, Chinnaiyan et al. (1) evaluated the correlation between
stress test results and extent of coronary artery disease (CAD) on
coronary computed tomography angiography (CCTA) and com-
pared the diagnostic performance of both noninvasive modalities
in patients undergoing invasive coronary angiograms. The authors
should be commended for their attempts to answer a pertinent
debate on appropriate use of various diagnostic modalities in
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July 17, 2012:235–41evaluation of CAD. However, a few interesting points arise from
the analysis, and several caveats have to be considered before
reaching a final conclusion.
First, authors defined obstructive CAD as coronary stenosis
50% rather than 70%, which might account for higher reported
sensitivity of CCTA in the study. It has been shown that 70%
stenosis is a better predictor of associated physiologically signifi-
cant perfusion defect and has more clinical implications (2). It
would be interesting to know whether the investigators have data
with regard to the degree of stenoses and perfusion defect, so that
more appropriate conclusions can be made before accepting the
study result that stress test did not predict obstructive CAD (1).
Moreover, the reported low yield of stress testing in the study can
be explained on the basis of work-up bias (inclusion of patients for
disease verification by a gold standard test based on the results of
preliminary testing) (3).
Second, the reason why asymptomatic patients underwent
invasive coronary angiography requires clarification, because there
is no clear benefit of revascularization in these patients; the same
also applies to patients with normal stress tests and nonobstructive
CAD on CCTA.
Third, the role of CCTA in asymptomatic patients is still not
established. With regard to the recommendations of the authors to
use CCTA in the asymptomatic individual with cardiac risk factors
instead of a stress test before surgery or beginning of a vigorous
exercise program, citing low positive predictive value (PPV) of
stress, it is important to note that most patients in the study the
authors quote here were symptomatic and that the study also
counted equivocal tests as positive while calculating PPV that
lowers the reported PPV (4).
Lastly, it would also be interesting to know whether the authors
made any attempt to study the impact of calcium score on the role
of CCTA as “gatekeeper” to invasive coronary angiography.
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